May be used as a marker of severe combined immunodeficiency (SCID); lack of adenosine deaminase (ADA) allows deoxyadenosine to accumulate and kill lymphocytes.
Sun, Tue, Thu
Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).
Do not freeze. Transport 1 mL whole blood.
Ambient: 15 days; Refrigerated: 15 days; Frozen: Unacceptable
Effective August 20, 2012
400-900 mU/g Hb
Adenosine Deaminase (ADA) deficiency is an autosomal recessive disorder of purine metabolism primarily affecting lymphocyte development, viability, and function. Affected individuals have less than 1 percent of normal ADA catalytic activity in red cell hemolysates. ADA deficiency is the cause of 20-30 percent of SCID cases. If the patient has been recently transfused, ADA deficiency may be masked; interpret results with caution. Heterozygotes cannot be identified by this test.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|0083001||Adenosine Deaminase RBC||47549-1|